APA Citatie

Park, K., Wan-Teck Lim, D., Okamoto, I., & Yang, J. C. (2019). First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting. Ther Adv Med Oncol.

Chicago Style citaat

Park, Keunchil, Darren Wan-Teck Lim, Isamu Okamoto, en James Chih-Hsin Yang. "First-line Afatinib for the Treatment of EGFR mutation-positive Non-small-cell Lung Cancer in the ‘real-world’ Clinical setting." Ther Adv Med Oncol 2019.

MLA citatie

Park, Keunchil, Darren Wan-Teck Lim, Isamu Okamoto, en James Chih-Hsin Yang. "First-line Afatinib for the Treatment of EGFR mutation-positive Non-small-cell Lung Cancer in the ‘real-world’ Clinical setting." Ther Adv Med Oncol 2019.